Both in Biotechnology
Entera Bio vs Allogene Therapeutics
Over the past year ENTX returned +13.5% and ALLO returned −2.5%; their daily moves had a correlation of 0.06.
ENTX +13.5% ALLO −2.5%Growth of $1, one year, split-adjusted
| Metric | ENTX | ALLO |
|---|---|---|
| Price | $3.20 | $1.18 |
| Market cap | $556.6M | $407.7M |
| Today | +2.56% | −5.60% |
| 1 month | +10.7% | −23.4% |
| 6 months | +190.9% | −45.1% |
| Year to date | +64.9% | −13.9% |
| 1 year | +17.2% | −3.3% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | 100.0% |
| Net margin | — | −919.8% |
| P/E (TTM) | — | — |
| Price / sales | — | 87.9× |
| Net cash | $11.0M | $332.6M |
| Dividend yield | — | — |
| Volatility (60d) | 61.9% | 53.4% |
| Short % of float | 3.5% | 19.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).